Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder

Frits A Wijburg, Grzegorz Węgrzyn, Barbara K Burton, Anna Tylki-Szymańska, Frits A Wijburg, Grzegorz Węgrzyn, Barbara K Burton, Anna Tylki-Szymańska

Abstract

Mucopolysaccharidosis III is a rare genetic disease characterized by progressive cognitive decline and severe hyperactivity that does not respond to stimulants. Somatic features are relatively mild. Patients are often initially misdiagnosed as having idiopathic developmental delay, attention deficit/hyperactivity disorder and/or autism spectrum disorders, putting them at risk for unnecessary testing and treatments.

Conclusion: Children with developmental or speech delay, especially those with a characteristic somatic feature or behavioural abnormalities, should be screened for MPS III.

©2013 The Author(s)/Acta Paediatrica ©2013 Foundation Acta Paediatrica.

Figures

Figure 1
Figure 1
Gallery of facial images from patients of various ages with MPS III. Not all affected patients have discernible facial dysmorphisms. Because of the variability in disease progression, early diagnosis does not always mean diagnosis in a young child; here we represent a variety of ages. The sex, MPS III subtype and age of the patients are as follows: (a) male, MPS IIIC, 10 years; (b) male, MPS IIIB, 21 years; (c) male, MPS IIIA, 43 years; (d) male, MPS IIIC, 10 years; (e) female, MPS IIIC, 13 years; (f) female, MPS IIIB, 18 years; (g) male, MPS IIIB, 11 years; (h) female, MPS IIIC, 4 years; (i) female, MPS IIIA, 20 years; (j) male, MPS IIIA, 10 years; (k) male, MPS IIIA, 6 years; (l) male, MPS IIIA, 11 years; (m) female, MPS IIIB, 20 years; (n) male, MPS IIIA, 12 years; (o) female, MPS IIIA, 14 years. MPS III, mucopolysaccharidosis type III.
Figure 2
Figure 2
Diagnostic algorithm for mucopolysaccharidosis (MPS) III. MPS III, mucopolysaccharidosis type III; uGAG, urinary glycosaminoglycan.

References

    1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, editor. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001.
    1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–54.
    1. Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis. 2008;31:240–52.
    1. Ruijter GJ, Valstar MJ, van de Kamp JM, van der Helm RM, Durand S, van Diggelen OP, et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab. 2008;93:104–11.
    1. Valstar MJ, Bruggenwirth HT, Olmer R, Wevers RA, Verheijen FW, Poorthuis BJ, et al. Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype. J Inherit Metab Dis. 2010;33:759–67.
    1. Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJ, Wevers RA, et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol. 2010;68:876–87.
    1. Valstar MJ, Bertoli-Avella AM, Wessels MW, Ruijter GJ, de Graaf B, Olmer R, et al. Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations. Hum Mutat. 2010;31:E1348–60.
    1. de Ruijter J, Valstar MJ, Wijburg FA. Mucopolysaccharidosis type III (Sanfilippo syndrome): emerging treatment strategies. Curr Pharm Biotechnol. 2011;12:923–30.
    1. van de Kamp JJ, Niermeijer MF, von Figura K, Giesberts MA. Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C) Clin Genet. 1981;20:152–60.
    1. Valstar MJ, Marchal JP, Grootenhuis M, Colland V, Wijburg FA. Cognitive development in patients with mucopolysaccharidosis type III (Sanfilippo syndrome) Orphanet J Rare Dis. 2011;6:43.
    1. Malm G, Mansson JE. Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period. Acta Paediatr. 2010;99:1253–7.
    1. Meyer A, Kossow K, Gal A, Muhlhausen C, Ullrich K, Braulke T, et al. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A) Pediatrics. 2007;120:e1255–61.
    1. Moog U, van Mierlo I, van Schrojenstein Lantman-de Valk HM, Spaapen L, Maaskant MA, Curfs LM. Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems? Am J Med Genet C Semin Med Genet. 2007;145C:293–301.
    1. Moog U. Sanfilippo B in an elderly female psychiatric patient: a rare but relevant diagnosis in presenile dementia. (Invited comment) Acta Psychiatr Scand. 2010;122:166.
    1. Heron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, Caillaud C, et al. Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. Am J Med Genet A. 2011;155A:58–68.
    1. Bax MC, Colville GA. Behaviour in mucopolysaccharide disorders. Arch Dis Child. 1995;73:77–81.
    1. Fraser J, Wraith JE, Delatycki MB. Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians. Clin Genet. 2002;62:418–21.
    1. White KK, Karol LA, White DR, Hale S. Musculoskeletal manifestations of Sanfilippo syndrome (mucopolysaccharidosis type III) J Pediatr Orthop. 2011;31:594–8.
    1. Andrade F, Prieto JA, Elorz J, Martin S, Sanjurjo P, Aldamiz-Echevarria L. Stability of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Clin Chim Acta. 2008;388:73–7.
    1. de Jong JG, Hasselman JJ, van Landeghem AA, Vader HL, Wevers RA. The spot test is not a reliable screening procedure for mucopolysaccharidoses. Clin Chem. 1991;37:572–5.
    1. Mabe P, Valiente A, Soto V, Cornejo V, Raimann E. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clin Chim Acta. 2004;345:135–40.
    1. Byers S, Rozaklis T, Brumfield LK, Ranieri E, Hopwood JJ. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS. Mol Genet Metab. 1998;65:282–90.
    1. Chih-Kuang C, Shuan-Pei L, Shyue-Jye L, Tuen-Jen W. MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in Sanfilippo and Morquio syndromes. J Clin Lab Anal. 2002;16:253–8.
    1. Gray G, Claridge P, Jenkinson L, Green A. Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses: an evaluation. Ann Clin Biochem. 2007;44:360–3.
    1. Mahalingam K, Janani S, Priya S, Elango EM, Sundari RM. Diagnosis of mucopolysaccharidoses: how to avoid false positives and false negatives. Ind J Pediatr. 2004;71:29–32.
    1. Auray-Blais C, Bherer P, Gagnon R, Young SP, Zhang HH, An Y, et al. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Mol Genet Metab. 2011;102:49–56.
    1. Auray-Blais C, Lavoie P, Zhang H,R, Clarke JT, Maranda B, et al. An improved method for glycosaminoglycan analysis by LC-MS/MS of urine samples collected on filter paper. Clin Chim Acta. 2012;413:771–8.
    1. Martell LA, Cunico RL, Ohh J, Fulkerson W, Furneaux R, Foehr ED. Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis. 2011;3:1855–66.
    1. Nielsen TC, Rozek T, Hopwood JJ, Fuller M. Determination of urinary oligosaccharides by high-performance liquid chromatography/electrospray ionization-tandem mass spectrometry: application to Hunter syndrome. Anal Biochem. 2010;402:113–20.
    1. Marsh J, Fensom AH. 4-Methylumbelliferyl alpha-N-acetylglucosaminidase activity for diagnosis of Sanfilippo B disease. Clin Genet. 1985;27:258–62.
    1. Voznyi Ya V, Karpova EA, Dudukina TV, Tsvetkova IV, Boer AM, Janse HC, et al. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease C (MPS III C) J Inherit Metab Dis. 1993;16:465–72.
    1. Karpova EA, Voznyi Ya V, Keulemans JL, Hoogeveen AT, Winchester B, Tsvetkova IV, et al. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type A (MPS IIIA) J Inherit Metab Dis. 1996;19:278–85.
    1. He W, Voznyi Ya V, Boer AM, Kleijer WJ, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type D (MPS IIID) J Inherit Metab Dis. 1993;16:935–41.
    1. Kleijer WJ, Karpova EA, Geilen GC, Keulemans JL, Huijmans JG, Tsvetkova IV, et al. Prenatal diagnosis of Sanfilippo A syndrome: experience in 35 pregnancies at risk and the use of a new fluorogenic substrate for the heparin sulphamidase assay. Prenat Diagn. 1996;16:829–35.
    1. Hopwood JJ. Prenatal diagnosis of Sanfilippo syndrome. Prenat Diagn. 2005;25:148–50.
    1. Dierks T, Schlotawa L, Frese MA, Radhakrishnan K, von Figura K, Schmidt B. Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease – lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim Biophys Acta. 2009;1793:710–25.
    1. Vance JM, Conneally PM, Wappner RS, Yu PL, Brandt IK, Pericak-Vance MA. Carrier detection in Sanfilippo syndrome type B: report of six families. Clin Genet. 1981;20:135–40.
    1. Fuller M, Tucker JN, Lang DL, Dean CJ, Fietz MJ, Meikle PJ, et al. Screening patients referred to a metabolic clinic for lysosomal storage disorders. J Med Genet. 2011;48:422–5.
    1. Piotrowska E, Jakobkiewicz-Banecka J, Tylki-Szymanska A, Czartoryska B, Wegrzyn A, Wegrzyn G. Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis. Acta Paediatr. 2009;98:743–9.
    1. Altarescu G, Renbaum P, Eldar-Geva T, Brooks B, Varshaver I, Avitzour M, et al. Preventing mucopolysaccharidosis type II (Hunter syndrome): PGD and establishing a Hunter (46, XX) stem cell line. Prenat Diagn. 2011;31:853–60.
    1. Tomi D, Schultze-Mosgau A, Eckhold J, Schopper B, Al-Hasani S, Steglich C, et al. First pregnancy and life after preimplantation genetic diagnosis by polar body analysis for mucopolysaccharidosis type I. Reprod Biomed Online. 2006;12:215–20.
    1. Qubbaj W, Al-Aqeel AI, Al-Hassnan Z, Al-Duraihim A, Awartani K, Al-Rejjal R, et al. Preimplantation genetic diagnosis of Morquio disease. Prenat Diagn. 2008;28:900–3.
    1. de Ru MH, Bouwman MG, Wijburg FA, van Zwieten MC. Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening. Mol Genet Metab. 2012;107:501–7.
    1. Fletcher J, Wilcken B. Neonatal screening for lysosomal storage disorders. Lancet. 2012;379:294–5.
    1. The human gene mutation database. Cardiff: Institute of Medical Genetics in Cardiff, Cardiff University; Available at from URL . (accessed on August 2, 2012)
    1. Yogalingam G, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: diagnostic, clinical, and biological implications. Hum Mutat. 2001;18:264–81.
    1. Souillet G, Guffon N, Maire I, Pujol M, Taylor P, Sevin F, et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003;31:1105–17.
    1. Yamada Y, Kato K, Sukegawa K, Tomatsu S, Fukuda S, Emura S, et al. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant. 1998;21:629–34.
    1. Herskhovitz E, Young E, Rainer J, Hall CM, Lidchi V, Chong K, et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis. 1999;22:50–62.
    1. Sivakumur P, Wraith JE. Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. J Inherit Metab Dis. 1999;22:849–50.
    1. Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet. 1995;345:1398–402.
    1. Sanberg PR, Eve DJ, Willing AE, Garbuzova-Davis S, Tan J, Sanberg CD, et al. The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells. Cell Transplant. 2011;20:85–94.
    1. Dickson PI, Chen AH. Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients. Curr Pharm Biotechnol. 2011;12:946–55.
    1. Tsai TH. Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A. 2005;1073:317–22.
    1. Guffon N, Bin-Dorel S, Decullier E, Paillet C, Guitton J, Fouilhoux A. Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study. J Pediatr. 2011;159:838–44. .e1.
    1. Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A, Brown JR, Crawford BE, et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS ONE. 2010;5:e14192.
    1. Delgadillo V, O'Callaghan MM, Artuch R, Montero R, Pineda M. Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis. 2011;34:1039–44.
    1. Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A, Tylki-Szymanska A, Puk E, Liberek A, et al. Two-year follow-up of Sanfilippo disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit. 2011;17:CR196–202.
    1. de Ruijter J, Valstar MJ, Narajczyk M, Wegrzyn G, Kulik W, Ijlst L, et al. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol. 2012;71:110–20.
    1. Węgrzyn A. Gene expression-targeted isoflavone therapy. IUBMB Life. 2012;64:307–15.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅